Compugen Ltd. - Product Pipeline Review - 2016

  • ID: 3734764
  • Company Profile
  • 48 pages
  • Global Markets Direct
1 of 4
Compugen Ltd. - Product Pipeline Review - 2016

Summary

‘Compugen Ltd. - Product Pipeline Review - 2016’, provides an overview of the Compugen Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Compugen Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Compugen Ltd.
- The report provides overview of Compugen Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Compugen Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Compugen Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Compugen Ltd.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Compugen Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Compugen Ltd.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Compugen Ltd. Snapshot

Compugen Ltd. Overview

Key Information

Key Facts

Compugen Ltd. - Research and Development Overview

Key Therapeutic Areas

Compugen Ltd. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

Compugen Ltd. - Pipeline Products Glance

Compugen Ltd. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Compugen Ltd. - Drug Profiles

CGEN-15001

Product Description

Mechanism of Action

R&D Progress

CGEN-15021

Product Description

Mechanism of Action

R&D Progress

CGEN-15031

Product Description

Mechanism of Action

R&D Progress

CGEN-15051

Product Description

Mechanism of Action

R&D Progress

CGEN-15091

Product Description

Mechanism of Action

R&D Progress

CGEN-25009

Product Description

Mechanism of Action

R&D Progress

CGEN-856S

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Inhibit CGEN-15049 for Cancer

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Inhibit CGEN-15052 for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Inhibit CGEN-15092 for Multiple Sclerosis

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody 1 to Inhibit CGEN-15029 for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody 2 to Target B7/CD28 for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody 3 to Target B7/CD28 for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody 4 to Target B7/CD28 for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody 5 to Target B7/CD28 for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody Conjugate 2 for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody Conjugates 1 for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody for Cancer

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Inhibit CGEN-15027 for Oncology

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Target CGEN-928 for Multiple Myeloma

Product Description

Mechanism of Action

R&D Progress

Compugen Ltd. - Pipeline Analysis

Compugen Ltd. - Pipeline Products by Target

Compugen Ltd. - Pipeline Products by Molecule Type

Compugen Ltd. - Pipeline Products by Mechanism of Action

Compugen Ltd. - Recent Pipeline Updates

Compugen Ltd. - Dormant Projects

Compugen Ltd. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Compugen Ltd., Key Information

Compugen Ltd., Key Facts

Compugen Ltd. - Pipeline by Indication, 2016

Compugen Ltd. - Pipeline by Stage of Development, 2016

Compugen Ltd. - Monotherapy Products in Pipeline, 2016

Compugen Ltd. - Out-Licensed Products in Pipeline, 2016

Compugen Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2016

Compugen Ltd. - Preclinical, 2016

Compugen Ltd. - Discovery, 2016

Compugen Ltd. - Pipeline by Target, 2016

Compugen Ltd. - Pipeline by Molecule Type, 2016

Compugen Ltd. - Pipeline Products by Mechanism of Action, 2016

Compugen Ltd. - Recent Pipeline Updates, 2016

Compugen Ltd. - Dormant Developmental Projects,2016

Compugen Ltd., Subsidiaries

List of Figures

Compugen Ltd. - Pipeline by Indication, 2016

Compugen Ltd. - Pipeline by Stage of Development, 2016

Compugen Ltd. - Monotherapy Products in Pipeline, 2016

Compugen Ltd. - Pipeline by Target, 2016

Compugen Ltd. - Pipeline by Molecule Type, 2016

Compugen Ltd. - Pipeline Products by Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll